List of Repurposed/505(b)(2) Drugs Companies in Denmark - 2

AFYX is an innovative niche developer of pharmaceuticals aiming at securing better treatments of diseases with unmet medical needs, such as cancer, women's health and severe pain. Our Research & Development, as well as reformulation of pharmaceuticals based on our patented technologies, helps to improve challenging health issues. We believe our focus will change people's lives. Dr. Claus J. Møller-San Pedro is the company CEO. Dr. Møller co-founded and secured successful IPOs of 3 companies in the BioPharma Industry (OXiGENE, Inc; Genmab A/S and Y-mAbs Therapeutics, Inc.) OUR HISTORY is based on the merger of three great and innovative companies bringing significant synergies together – the companies were: INPHENA A/S, a company that already has commercial activities in several countries and develop repurposed existing pharmaceutical substances for new indications. LIONHEART, a company focused on treatment of chronic and intermittent cluster headache. A dramatic a severely debilitating disease with limited treatment options available – We have patent protection for the use of ketamine as nasal administration in this indication. AFYX THERAPEUTICS A/S, a company based on development of a proprietary patented patch technology that sticks to wet surfaces and delivers pharmaceutical products locally where the patch is applied. Our two first projects focus on inflammatory diseases in the oral cavity – oral lichen planus – also a significant unmet medical need and precancerous stages of head and neck cancer in the mouth where we aim to develop a chemotherapy containing patch.

Reponex Pharmaceuticals A/S is a small Danish pharmaceutical company dedicated to the development of new, effective treatments for diseases that have significant patient and social impact and for which current therapy is lacking or in need of improvement. The diseases may be acute and life threatening, such as bacterial peritonitis, or chronic diseases that spoil the quality of life and may shorten it, such as inflammatory bowel diseases, or complications of chronic diseases such as the disabling non-healing skin ulcers in patients with diabetes or venous insufficiency. There is a continuing medical need to improve the treatment of these difficult conditions